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Purpose: We undertook an observational study to investigate the effects of immuno-
suppressive treatment on proteinuria and renal function in 179 Korean idiopathic 
membranous nephropathy patients with nephrotic syndrome. Materials and Meth-
ods: The primary outcome was regarded as the first appearance of remission and the 
secondary outcomes as a decline in estimated glomerular filtration rate (eGFR) >50% 
or initiation of dialysis, and all-cause mortality. Seventy-two (40.2%) and 50 (27.9%) 
patients were treated with corticosteroids alone (C) and corticosteroids plus cyclospo-
rine (C+C), respectively, whereas 57 (31.8%) did not receive immunosuppressants 
(NTx). Cyclosporine was added if there was no reduction in proteinuria of >50% 
from baseline by corticosteroids alone within 3 months. Results: There were no dif-
ferences in baseline renal function and the amount of proteinuria among the three 
groups. Overall, complete remission (CR) was achieved in 88 (72.1%) patients by im-
munosuppressants. In a multivariate analysis adjusted for covariates associated with 
adverse renal outcome, the probability of reaching CR was significantly higher in the 
C [hazard ratio (HR), 4.09; p<0.001] and C+C groups (HR, 2.57; p=0.003) than in the 
NTx group. Kaplan-Meier analysis revealed that 5-year CR rates of C, C+C, and NTx 
groups were 88.5%, 86.2%, and 56.7% (p<0.001). Ten-year event-free rates for the 
secondary endpoints in these three groups were 91.7%, 79.9%, and 57.2% (p=0.01). 
Conclusion: Immunosuppressive treatment was effective in inducing remission and 
preserving renal function in these patients. Therefore, stepwise treatment using corti-
costeroids alone and in combination with cyclosporine is warranted in these patients.
Key Words:   Corticosteroids, cyclosporine, idiopathic membranous nephropathy, 
nephrotic syndrome, remission
INTRODUCTION
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in 
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impact of corticosteroids with or without cyclosporine on 
the outcome of IMN in East Asian patients. In this study, 
we aimed to elucidate the remission and renal survival rates 
in adult Korean patients with biopsy proven IMN, who pre-
sented with nephrotic syndrome and were followed up for 
more than 1 year, according to a three stage therapeutic 
strategy; conservative treatment, corticosteroids alone, and 
corticosteroids plus cyclosporine.
MATERIALS AND METHODS
　　　
Ethics statement
This study was carried out in accordance with the Declara-
tion of Helsinki and approved by the Institutional Review 
Board (IRB) of Yonsei University College of Medicine 
Clinical Trial Center. All patients participated in the current 
study were aware of this investigation. However, since this 
study was a retrospective medical record-based study and 
the study subjects were de-identified, the IRB waived the 
need for written consent from the patients.
   
Study subjects and data collection
Between January 1990 and December 2009, 470 patients 
were diagnosed as having MN by renal biopsy at Yonsei 
University Severance Hospital in Seoul, Korea. Of the ini-
tial 470 MN patients, we excluded patients younger than 18 
years old, patients with other diseases including systemic 
lupus erythematosus, diabetes mellitus, malignancy, and 
systemic infection, patients with a previous history of kid-
ney transplantation or exposure to drugs associated with 
MN, such as gold, penicillamine, and captopril, patients 
with positive hepatitis B virus antigen or hepatitis C virus 
antibody, and patients with a follow-up duration of less than 
1 year. Patients with proteinuria of a non-nephrotic range 
were also excluded (Fig. 1). Nephrotic syndrome was diag-
nosed based on heavy proteinuria of more than 3.5 g/day, 
hypoalbuminemia of less than 3.5 g/dL, the presence of 
edema, and hypercholesterolemia. Demographic and clini-
cal data were reviewed retrospectively for age, gender, med-
ical history, presenting symptoms, medications, response to 
treatment, time to remission, and follow-up duration and 
were recorded from the time of renal biopsy until the devel-
opment of ESRD or the end of follow-up. The following 
laboratory data at the time of renal biopsy were collected: 
urinalysis, 24-hour urinary protein excretion, urinary pro-
tein-to-creatinine ratio, hemoglobin, blood urea nitrogen, 
adults. Even though MN can be accompanied by a wide 
spectrum of disease, including tumors, infections, autoim-
mune diseases, and drugs, the idiopathic form remains the 
most common. The natural course of idiopathic MN (IMN) 
varies from a spontaneous remission to progression to end-
stage renal disease (ESRD). Approximately one-third of pa-
tients experience spontaneous remission, another third 
show persistent proteinuria, and the remaining third prog-
ress to ESRD.1 These variable courses of IMN cause physi-
cians great difficulty in deciding whether to treat and, if so, 
what kind of drugs should be used.
Previous studies have shown that heavy proteinuria, arte-
rial hypertension, renal insufficiency at presentation, and se-
vere histologic lesions are associated with renal survival in 
IMN patients with nephrotic syndrome.1-3 Among these risk 
factors, persistent heavy proteinuria is the most reliable pre-
dictor of life-threatening complications and poor renal out-
come in these patients.1-3 Therefore, aggressive treatments to 
induce complete or partial remission or to reduce the 
amount of proteinuria have been tested. Previous random-
ized control trials found that corticosteroids alone were not 
effective in IMN patients of Western patients with nephrotic 
syndrome in terms of preserving renal function and long 
term proteinuria reduction.4,5 These results led to the sugges-
tion that a 6-month combination therapy with alternating 
corticosteroids and alkylating agents, either chlorambucil or 
cyclophosphamide, should be considered as the first-line of 
treatment in IMN patients with nephrotic syndrome.6-9 How-
ever, many physicians feel constrained when prescribing 
these cytotoxic agents due to the potential risks of marrow 
toxicity, gonadal dysfunction, and malignancy.10-12
Compared to studies on Western patients, the prognosis 
of IMN and response to drugs seem to be more favorable in 
East Asian patients. One study demonstrated that renal sur-
vival rates were relatively high in Japanese IMN patients 
with nephrotic syndrome. In addition, another study showed 
that treatment responses to corticosteroids alone or with 
other immunosuppressants were more favorable in Japa-
nese and Chinese IMN patients.13-15 In both of these studies, 
the majority of patients received cyclophosphamide as the 
adjunctive drug to corticosteroids. In addition, since the ran-
domized trials by Cattran, et al.16,17 revealed that cyclospo-
rine was effective in inducing remission in steroid-resistant 
MN with nephrotic syndrome and in MN patients with pro-
gressive renal insufficiency and heavy proteinuria, the ben-
eficial effect of cyclosporine in MN has been frequently re-
ported. However, there has been no investigation on the 
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Statistical analysis
Statistical analyses were performed using the statistical pack-
age SPSS for Windows version 13.0 (SPSS Inc., Chicago, 
IL, USA). All data were expressed as means±SD or as per-
centages. Continuous data were analyzed using one-way 
ANOVA or Kruskal-Wallis test according to treatment mo-
dalities, and significant differences were further confirmed by 
the Student’s t-test or Mann-Whitney U test, respectively. For 
categorical variables, the chi-square or Fisher’s exact test was 
used for multiple comparison. To identify independent fac-
tors associated with CR and CR+PR, multivariate Cox re-
gression analysis was performed including all covariates with 
a p-value of <0.1 on univariate analysis. Even though a p-
value was ≥0.1, potential confounding factors that were tradi-
tionally known as significant prognostic determinants of 
IMN1-3 were also included in the multivariate analysis. In re-
sult, covariates such as age, sex, blood pressure, baseline 
eGFR, proteinuria, RAS blockades use, and pathologic stag-
es were entered in the multivariate models. Kaplan-Meier 
analyses and log rank tests were used to compare the differ-
ences in reaching CR or PR, and the secondary outcomes. p-
values less than 0.05 were considered statistically significant.
 
RESULTS
 
Baseline characteristics of patients
A total of 179 IMN patients with nephrotic syndrome were 
serum creatinine, albumin, and total cholesterol levels. The 
estimated glomerular filtration rate (eGFR) was calculated 
using the 4-variable Modification of Diet in Renal Disease 
study formula. The stages of MN, which were reported 
from I to IV, were also reviewed.18
Treatment of patients
Conservative treatment, including dietary salt restriction, re-
nin-angiotensin system (RAS) blockades or other anti-hy-
pertensive medications, diuretics, and/or HMG co-A reduc-
tases (statins), was given to nearly all patients. In general, 
immunosuppressive therapy was initiated in patients with 
nephrotic range proteinuria for more than 3 months, serious 
complications of nephrotic syndrome such as venous throm-
boemboli and intractable edema, or rapidly deteriorating re-
nal function. The first-line immunosuppressive drug was 
corticosteroids at a dose of 1 mg/kg/day. If there was no re-
duction in proteinuria of more than 50% from the baseline 
value by corticosteroids within 3 months, cyclosporine A 
was added along with 0.5 mg/kg/day corticosteroids. The 
initial cyclosporine A dose of 3 mg/kg/day was later adjust-
ed aiming at 12-hour trough levels between 100 and 150 
µg/L. In a minority of patients, cyclophosphamide at a dose 
of 2 mg/kg/day or mycophenolate mofetil at doses up to 2 
g/day was used as a second-line drug.
   
Outcomes
The primary outcome was the first appearance of complete 
remission (CR) or partial remission (PR). Complete remis-
sion was defined as the absence of proteinuria (urinary pro-
tein excretion less than 0.3 g/day or a urinary protein-to-cre-
atinine ratio of less than 0.3) and trace or negative urinary 
albumin on a dipstick test with the disappearance of edema 
and normalization of biochemical findings such as hypoal-
buminemia and hypercholesterolemia. Partial remission was 
defined as a reduction in proteinuria by more than 50% from 
baseline and <3.5 g/day or urinary protein-to-creatinine ratio 
of <3.5. If neither of these remissions was achieved, the re-
sults were defined as no response to treatment. Relapse was 
defined as the reappearance of significant proteinuria of more 
than 3.5 g/day and edema in patients on remission. Mean-
while, secondary outcomes were considered as a decline in 
eGFR of more than 50% of baseline value or a requirement 
of renal replacement therapy, and all-cause mortality. During 
follow-up, complete or partial remission, spontaneous remis-
sion, relapse, deterioration of renal function, ESRD, and 
death were recorded.
Fig. 1. Flow-chart of the enrolment procedure. A total of 470 patients were 
diagnosed as membranous nephropathy (MN). Patients with an age of less 
than 18 years, patients with other diseases including systemic lupus ery-
thematosus, diabetes mellitus, and malignancy, patients with previous his-
tory of kidney transplantation or exposure to drugs associated with MN, 
such as gold, penicillamine, and captopril, patients with positive hepatitis B 
virus antigen or hepatitis C virus antibody, and patients with a follow-up 
duration of less than 1 year were excluded. Finally, patients with protein-
uria of non-nephrotic range were also excluded.
Excluded (n=254)
Excluded (n=37)
Non-nephrotic (n=37)
Idiopathic MN with nephrotic syndrome (n=179)
Children (n=34)
SLE (n=19)
Cancer (n=23)
Biopsy-proven MN after kidney 
  transplantation (n=19)
Previous drug history (n=4)
B viral hepatitis (n=62)
C viral hepatitis (n=6)
Follow-up loss (n=98)
MN (n=470)
Idiopathic MN (n=216)
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Baseline clinical and laboratory parameters were com-
pared among the three groups; conservative treatment, cor-
ticosteroids alone, and corticosteroids plus cyclosporine 
groups. Compared to the conservative treatment group, the 
mean age was significantly younger (p<0.001), serum cho-
lesterol concentrations were significantly higher (p=0.003), 
and serum albumin levels were significantly lower (p=0.003) 
in patients treated with corticosteroids alone. There were 
also significant differences in serum cholesterol concentra-
tions between the conservative treatment and corticoste-
roids plus cyclosporine groups (p=0.04). However, post-
hoc tests revealed that serum cholesterol and albumin levels 
were comparable between patients with corticosteroids alone 
and with corticosteroids plus cyclosporine. On the other 
hand, there were no significant differences in the proportion 
of male patients, serum creatinine concentrations, eGFR, 
24-hour urinary protein excretion, and the stage of MN 
among the three groups (Table 1).
   
Response to treatment in terms of nephrotic syndrome
Kaplan-Meier analysis revealed that cumulative probabili-
ties to achieve CR and to achieve CR or PR were signifi-
cantly higher in the corticosteroids alone and corticoste-
roids plus cyclosporine groups compared to patients with 
included in the present study. The mean age of patients at the 
time of renal biopsy was 52.1 years, 102 patients (57.0%) 
were males, and the mean follow-up duration was 56.9± 
52.5 months. Twenty-five patients (14.0%) had hyperten-
sion and the mean serum creatinine, albumin, and choles-
terol concentrations were 1.1±0.5, 2.7±0.7, and 306.4±99.5 
mg/dL, respectively. The mean 24-hour urinary protein ex-
cretion values were 7.5±4.2 g/day. RAS blockades such as 
angiotensin converting enzyme inhibitors or angiotensin II 
receptor blockers were prescribed in 161 patients (89.9%) 
and statins in 146 patients (81.6%). Renal biopsy findings 
revealed MN with stage I, II, III, and IV in 51 (28.0%), 84 
(46.9%), 42 (23.5%), and 2 patients (1.1%), respectively 
(Table 1).
   
Comparison of clinical and laboratory parameters 
according to treatment modality
Among the 179 patients, 72 (40.2%) received only cortico-
steroids treatment, while 50 patients (27.9%) received both 
cyclosporine and corticosteroids. Cyclophosphamide or 
mycophenolate mofetil combined with corticosteroids were 
given in 4 patients (0.02%) and 1 patient (0.01%), respec-
tively. The remaining 57 patients (31.8%) did not receive 
any immunosuppressants during the follow-up.
Table 1. Baseline Characteristics According to Treatment Modalities
Variables Total (n=179)
Conservative 
treatment (n=57)
Corticosteroids 
alone (n=72)
Corticosteroids 
plus CsA (n=50)
p value
Age (yrs)   52.1±13.9   57.5±11.1   47.2±15.3*   52.8±13.9 <0.01
Male (%) 102 (57)    30 (52.6) 47 (65.3) 25 (50)   0.84
MAP (mm Hg)   97.2±31.0   94.8±12.6 94.5±15.7 103.9±53.7   0.19
Follow-up duration (months)   56.9±52.5   48.5±48.7 70.9±58.5   49.6±48.7   0.03
Serum creatinine (mg/dL)   1.1±0.5   1.1±0.5 1.1±0.7 0.99±0.3   0.46
eGFR (mL/min/1.73 m2)   79.7±27.0   74.6±29.3 81.9±25.6   74.6±29.3   0.22
Serum cholesterol (mg/dL) 306.4±99.5 270.0±74.8 327.9±98.9*    316.6±113.9† <0.01
Serum albumin (g/dL)   2.7±0.7   2.9±0.6   2.5±0.7*   2.7±0.8 <0.01
Proteinuria (g/day)   7.5±4.2   6.9±3.7 7.9±4.7   7.6±4.1   0.34
Statin use (%)   146 (81.6)    48 (84.2) 54 (75.0)    44 (88.0)   0.67
RAS blockades use (%)   161 (89.9)    54 (94.7) 60 (83.3)    47 (94.0)   0.82
Pathologic stage (%)   0.46
    I     51 (28.5)    17 (29.8) 21 (29.2)    13 (26.0)
    II     84 (46.9)    28 (49.1) 32 (44.4)    24 (48.0)
    III     42 (23.5)    12 (21.1) 18 (25.0)    12 (24.0)
    IV     2 (1.1) 0 (0) 1 (1.4)    1 (2.0)
CsA, cyclosporine A; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate (by MDRD-4 equation); RAS, renin-angiotensin system; 
MDRD, Modification of Diet in Renal Disease study.
Values are expressed as mean±standard deviation or number (percentage).
*p<0.01 vs. conservative treatment. 
†p<0.05 vs. conservative treatment.
Immunosuppressive Treatment in IMN
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Response to treatment in terms of renal outcome and 
all-cause mortality
The numbers of patients who experienced renal outcome, 
which was defined as a decline in eGFR of more than 50% 
of baseline value or a requirement of renal replacement ther-
apy, were 10 (17.5%) in the conservative treatment, 5 (6.9%) 
in the corticosteroids alone, and 5 (10.0%) in the corticoste-
roids plus cyclosporine group. During the follow-up period 
2 patients (3.5%) in the conservative treatment group died 
of acute myocardial infarction and cerebral infarction, and 
2 deaths due to acute myocardial infarctions were observed 
in the corticosteroids plus cyclosporine group, while no 
mortality was noticed in patients treated with corticosteroids 
alone. Even though the 5-year event-free rates for the com-
posite secondary endpoints of renal outcome and all-cause 
mortality were comparable among the three groups (conser-
vative treatment, 82.6%; corticosteroids alone, 91.7%; and 
corticosteroids plus cyclosporine, 86.5%; p=0.41), the 10-
year event-free rates for the secondary endpoints were sig-
nificantly higher in patients treated with corticosteroids alone 
(91.7%) and with corticosteroids plus cyclosporine (79.9%) 
conservative treatment. The 1-year CR rates in the conser-
vative treatment, corticosteroids alone, and corticosteroids 
plus cyclosporine groups were 10.5%, 61.5%, and 42.9%, 
respectively (p<0.001). In addition, the 5-year CR rates in 
these three groups were 56.7%, 88.5%, and 86.2%, respec-
tively (p<0.001) (Fig. 2A). Considering either CR or PR, 
the overall 1-year remission rates according to three thera-
peutic modalities were 42.4%, 97.0%, and 86.2%, respec-
tively (p<0.001) (Fig. 2B).
In a multivariate analysis adjusted for age, sex, blood 
pressure, baseline eGFR, proteinuria, RAS blockades use, 
and pathologic stages, the probability of reaching CR was 
significantly higher in the corticosteroids alone [hazard ra-
tio (HR), 4.09; 95% CI, 2.34-7.15; p<0.001] and corticoste-
roids plus cyclosporine groups (HR, 2.57; 95% CI, 1.45-
4.57; p=0.003) compared to patients with conservative 
treatment (Table 2). Corticosteroids alone (HR, 4.74; 95% 
CI, 2.94-7.64; p<0.001) and corticosteroids plus cyclospo-
rine treatment (HR, 3.51; 95% CI, 2.16-5.71; p<0.001) 
were also significantly associated with an increased proba-
bility of reaching CR or PR (Table 2).
Fig. 2. Kaplan-Meier plots for cumulative probabilities to achieve complete remission (CR) and to achieve CR or partial remission (PR) according to treatment 
modalities. (A) Probability to achieve CR was significantly higher in patients treated with corticosteroids alone or with cyclosporine A (CsA) compared to pa-
tients with conservative treatment (Tx). (B) Probability to achieve CR or PR was significantly higher in patients treated with corticosteroids alone or with CsA 
compared to patients with conservative Tx.
Table 2. Multiple Cox Regression Analysis for CR, and CR or PR Adjusted for Covariates
Treatment modality
CR CR or PR
HR (95% CI)* p value HR (95% CI)* p value
Conservative treatment Reference Reference
Corticosteroids alone 4.09 (2.34-7.15) <0.001 4.74 (2.94-7.64) <0.001
Corticosteroids plus CsA 2.57 (1.45-4.57)   0.003 3.51 (2.16-5.71) <0.001
CR, complete remission; PR, partial remission; CsA, cyclosporine A; eGFR, estimated glomerular filtration rate.
*Adjusted for age, sex, blood pressure, baseline eGFR, proteinuria, renin-angiotensin system blockades use, and pathologic stage.
Corticosteroids alone
Corticosteroids+CsA
Conservative Tx
Corticosteroids alone
Corticosteroids+CsA
Conservative Tx
A B
72
50
57
  4
  2
12
4
1
2
3
0
1
0
0
0
0
0.2
0.4
0.6
0.8
1.0
Pr
ob
ab
ilit
y t
o 
ac
hi
ev
e 
CR
0 50 100 150 200
Follow-up (months)
p<0.001
  Corticosteroids alone  
  Corticosteroids+CsA   
  Conservative Tx
72
50
57
  1
  2
15
0
0
5
0
0
3
0
0
1
0
0
0
0
0.2
0.4
0.6
0.8
1.0
Pr
ob
ab
ilit
y t
o 
ac
hi
ev
e 
CR
 o
r P
R
0 20 40 8060 100
Follow-up (months)
p<0.001
  Corticosteroids alone  
  Corticosteroids+CsA   
  Conservative Tx
Dong Ho Shin, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 4   July 2013978
Characteristics of patients who experienced relapses
Table 4 shows the characteristics of patients who experi-
enced relapses according to three treatment modalities. Of 
all patients, 38 relapses occurred in 22 patients (11 patients 
with one relapse, 6 patients with two relapses, and 5 patients 
with three relapses); 3 (5.3%) in the conservative treatment 
group, 3 (4.2%) in the corticosteroids alone group, and 16 
patients (32.0%) in the corticosteroid plus cyclosporine 
group. During the follow-up, 17 patients (77.2%) achieved 
CR or PR. All patients in the conservative treatment group 
were treated with corticosteroids alone at the time of relaps-
es. In the corticosteroids alone group, corticosteroids plus 
cyclosporine were used in 2 patients at the time of 1st and 
2nd relapses and corticosteroids plus mycophenolate mofetil 
were used in 1 patient at the time of 3rd relapse. All patients 
in the corticosteroids plus cyclosporine group were treated 
with corticosteroids plus cyclosporine at the time of 1st re-
lapse, while corticosteroids plus cyclophosphamide and 
corticosteroids plus mycophenolate mofetil were used in 8 
patients at the time of 2nd relapse and in 4 patients at the 
time of 3rd relapse, respectively (Fig. 4).
DISCUSSION
The results of this retrospective study demonstrate that cor-
ticosteroids alone or with cyclosporine were effective in in-
ducing remission in Korean IMN patients with nephrotic 
syndrome. These treatment regimens were also indepen-
dently associated with an increased probability of achieving 
remission. In addition, the cumulative renal survival was 
significantly higher in patients treated with immunosuppres-
sants compared to patients who received only conservative 
treatment.
compared to the conservative treatment group (57.2%; p= 
0.01) (Fig. 3).
   
Adverse events
Cushingoid appearance was observed in all patients treated 
with corticosteroids. A life-threatening infection developed 
in 1 patient in the corticosteroids plus cyclosporine group, 
and newly-developed diabetes or impaired glucose toler-
ance was seen in 5 patients in the corticosteroids alone and 
1 patient in the corticosteroids plus cyclosporine group. In 
addition, 1 patient had transiently elevated liver enzyme 
and 2 patients experienced mild nausea after treatment with 
corticosteroids plus cyclosporine. Moreover, mild gum hy-
pertrophy was observed in 1 patient treated with corticoste-
roids plus cyclosporine (Table 3).
   
Fig. 3. Kaplan-Meier plots for the composite secondary endpoints, defined 
as renal outcome and all-cause mortality, according to treatment modali-
ties. The cumulative event-free rates were significantly higher in patients 
treated with corticosteroids alone or with cyclosporine A (CsA) compared 
to patients with conservative treatment (Tx).
Table 3. Adverse Events According to Treatment Modalities
Conservative treatment 
(n=57)
Corticosteroids alone 
(n=72)
Corticosteroids plus CsA 
(n=50)
Bone marrow depression (%) 0 (0) 0 (0)    2 (4.0)
Infection (%)    4 (7.0)    2 (2.8)    3 (6.0)
Life-threatening infection (%) 0 (0) 0 (0)    1 (2.0)
Impaired glucose tolerance (%) 0 (0)    4 (5.6)    1 (2.0)
Diabetes (%) 0 (0)    1 (1.4) 0 (0)
Elevated liver enzymes (%) 0 (0) 0 (0)    1 (2.0)
Gingival hyperplasia (%) 0 (0) 0 (0)    1 (2.0)
Myopathy (%) 0 (0)    2 (2.8) 0 (0)
Malaise (%) 0 (0) 0 (0)    2 (4.0)
Hospitalization (%)    1 (1.7)    2 (2.8)    3 (6.0)
CsA, cyclosporine A.
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when prescribing these drugs. Approximately 10% of pa-
tients have reported discontinuing treatment because of ad-
verse effects.12 Even though the incidence of malignancy in 
patients receiving cytotoxic drugs has been known to be 
comparable to that of the general Western population; how-
ever, leukopenia and infertility, of which Korean are more 
critically receptive, are additional problems. Due to the 
high cost of granulocyte colony stimulating factor (G-CSF) 
and a strict indication for insurance coverage, the use of G-
CSF has been limited in Korea. In addition, Koreans con-
sider infertility a serious disability even in the elderly. For 
these reasons, cyclosporine has been largely substituted for 
alkylating agents in Korea to treat nephrotic syndrome sec-
ondary to IMN.
Cyclosporine has been widely used in nephrotic patients 
with MCD or focal segmental glomerulosclerosis, particu-
Numerous studies on the alternative treatment regimens 
for IMN have been conducted because treatment with corti-
costeroids alone in IMN patients with nephrotic syndrome 
of Western countries is not as effective as in nephrotic pa-
tients with minimal changes disease (MCD) in terms of 
long-term proteinuria reduction and renal function preserva-
tion.4,5,19 The results of these studies were used to define the 
widely accepted Ponticelli regimen, a 6-month combination 
therapy with corticosteroids and cytotoxic agents such as 
chlorambucil and cyclophosphamide, which has been con-
sidered the first-line treatment regimen for IMN patients 
with nephrotic syndrome.6-9 In addition, two meta-analyses 
and a systematic review confirmed that only the treatment 
including cytotoxic agents increased the chance of remission 
of nephrotic syndrome in IMN patients.20-22 However, the 
side effects of alkylating agents make physicians hesitate 
Table 4. Characteristics of Patients, Who Experienced Relapses, According to Treatment Modalities
Variable
Conservative treatment 
(n=3)
Corticosteroids alone 
(n=3)
Corticosteroids plus CsA 
(n=16)
p value
Age (yrs)          59.2 (48.0-70.4)         50.1 (36.1-64.5) 49.3 (41-58) 0.28
Male (%)      1 (33.3)      2 (66.7)   6 (3.75) 0.63
Number of relapse (%) 0.86
    1 relapse      2 (66.7)      1 (33.3)   8 (50.0)
    2 relapses      1 (33.3)      1 (33.3)   4 (25.0)
    3 relapses 0 (0)      1 (33.3)   4 (25.0)
Follow-up primary endpoint (%) 0.26
    CR 0 (0)      1 (33.3)   9 (56.3)
    PR      1 (33.3)      1 (33.3)   5 (31.3)
    NR      2 (66.7)      1 (33.3)   2 (12.5)
Follow-up secondary endpoint (%) 0.12
    Renal outcome* 0 (0)      2 (66.7)   3 (18.8)
    All-cause mortality 0 (0) 0 (0)   2 (12.5)
CsA, cyclosporine A; CR, complete remission; PR, partial remission; NR, no response; eGFR, estimated glomerular filtration rate; IQR, InterQuartile Rate.
Values are expressed as median (IQR) or number (percentage).
*Defined as a decline in eGFR of more than 50% of baseline value or a requirement of renal replacement therapy.
Fig. 4. Flow-chart of the treatment regimens and therapeutic duration in patients who experienced relapses. Values are expressed as median (IQR). CsA, cy-
closporine A; CTx, cyclophosphamide; MMF, mycophenolate mofetil; IQR, InterQuartile Rate.
1st relapse 2nd relapse 3rd relapse
Conservative treatment (n=57)
Corticosteroids alone (n=72)
Corticosteroids plus CsA (n=50)
Corticosteroids alone (n=3)
2.8 (2.5-3.9) months
Corticosteroids alone (n=1)
6.9 months
Corticosteroids plus CsA (n=2)
7.5 (6.0-9.0) months
Corticosteroids plus CsA (n=16)
12.0 (8.0-13.0) months
Corticosteroids alone (n=1)
5.5 months
Corticosteroids plus CsA (n=2)
11.5 (11.0-12.3) months
Corticosteroids plus CTX (n=8)
6.5 (3.5-9.8) months
Corticosteroids plus MMF (n=1)
6 months
Corticosteroids plus MMF (n=4)
5.5 (4.5-6.9) months
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portion of patients on RAS blockades, and the severity of 
nephrotic syndrome in patients on conservative treatment. 
Meanwhile, since almost 20% of patients with conservative 
treatment still show progressive loss of renal function dur-
ing follow-up despite an initial favorable prognosis, these 
patients would have benefited from immunosuppressive 
therapy as well.
A number of previous studies have revealed that old age, 
male gender, hypertension, heavy proteinuria, and renal in-
sufficiency were significant risk factors for progression to 
ESRD in IMN patients with nephrotic syndrome.2,3 Cattran, 
et al.23 also found that the highest sustained 6-month period 
of proteinuria was the most important predictor of progres-
sion in patients with IMN. In addition, accumulating evi-
dence suggests that IMN patients with CR or PR remission 
have a significantly favorable clinical course compared to 
those with persistent nephrotic range proteinuria.22 There-
fore, reducing proteinuria as soon as possible may have a 
significant impact on the renal survival in these patients. In 
the current study, compared to the conservative treatment 
group, serum cholesterol levels were significantly higher 
and serum albumin concentrations were significantly lower 
in patients who were treated with corticosteroids alone or 
corticosteroids plus cyclosporine. Even though there was 
no statistical significance. Moreover, 24-hour urinary pro-
tein excretion was greater in these patients. These findings 
indicate that immunosuppressant treatment was given in 
more clinically severe patients. Nevertheless, CR or PR was 
more frequently observed in the immunosuppressive group. 
Immunosuppressive treatment was also found to be as the 
most significant independent predictor of achieving CR or 
PR. Furthermore, renal survival was better in patients who 
received immunosuppressive agents. Taken together, these 
findings indicate that corticosteroids alone or with cyclo-
sporine treatment may be required not only to induce re-
mission of proteinuria but also to preserve renal function in 
Korean IMN patients with severe nephrotic syndrome.
There are several limitations to our study. First, even 
though a relatively large number of IMN patients with ne-
phrotic syndrome were included from a single center, this 
study was a retrospective cohort study without any inter-
vention on treatment option. In addition, this nature of the 
present study could make inferences on the effect of corti-
costeroids treatment biased. Second, since there were no 
standardized indications for starting immunosuppressant 
drugs or continuing conservative treatment, the treatment 
decisions were dependent on the preferences of individual 
larly in patients who are steroid-resistant or steroid-depen-
dent, or in patients experiencing frequent relapses.23 In ad-
dition, Cattran, et al.16,17 demonstrated that cyclosporine 
significantly abrogated the rate of deterioration of renal 
function and reduced the amount of proteinuria in IMN pa-
tients at a high risk of progression and persistent nephrotic 
range proteinuria. Alexopoulos, et al.24 also found that cy-
closporine with or without corticosteroids was effective in 
inducing remission in the majority of nephrotic patients with 
IMN and well-preserved renal function. Based on these 
findings, the ‘Cyclosporine in Idiopathic Nephrotic Syn-
drome’ working group recommended that cyclosporine 
could be tried as a first-line option in IMN patients with ne-
phrotic syndrome either as monotherapy or in combination 
with corticosteroids.23 In the present study, however, pa-
tients at medium or high risk were not initially treated with 
cyclosporine. Instead, corticosteroids were used as the first-
line drug for these patients. Unlike patients of Western coun-
tries, East Asian patients with IMN responded well to corti-
costeroids alone.14 Tang, et al.15 demonstrated that treatment 
with corticosteroids alone for 6 months induced remission 
in 71% (5/7) of Chinese IMN patients with nephrotic syn-
drome. In addition, a retrospective multicenter study from 
Japan showed that corticosteroids alone induced CR and 
PR of proteinuria in 47.9% and 39.3% of IMN patients with 
nephrotic syndrome, respectively.14 The results of our study 
also found that 70 out of 122 patients (57.4%) responded to 
the initial treatment of corticosteroids alone. These findings 
suggest that biological origin may influence the therapeutic 
responsiveness to corticosteroids and that corticosteroids 
alone can be tried first in East Asian IMN patients with ne-
phrotic syndrome.
In this study, CR or PR occurred in 86.2% of our patients 
with conservative treatment, which was significantly higher 
compared to those found previously in Western studies.25 In 
contrast, even though the mean follow-up duration of this 
study was shorter than that of the multicenter study from 
Japan, the proportion of patients taking RAS blockades in 
the conservative treatment group was significantly higher 
(94.7% vs. 23.0%) in the present study, resulting in compa-
rable spontaneous remission rates with the Japan study.14 
Since spontaneous remission occurs progressively during 
the follow-up, and the use of RAS blockades and baseline 
proteinuria are significant independent predictors of sponta-
neous remission in IMN patients with nephrotic syndrome,25 
we infer that these divergent results may be attributed to the 
differences in biological origin, follow-up duration, the pro-
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phropathy and renal insufficiency: improved renal survival but 
high relapse rate. Nephrol Dial Transplant 2004;19:1142-8. 
13. Eriguchi M, Oka H, Mizobuchi T, Kamimura T, Sugawara K, Ha-
rada A. Long-term outcomes of idiopathic membranous nephropa-
thy in Japanese patients treated with low-dose cyclophosphamide 
and prednisolone. Nephrol Dial Transplant 2009;24:3082-8. 
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physician’s decision. Third, immunosuppressive treatment 
was usually initiated within 3 months in the IMN patients 
with severe nephrotic syndrome. Recently, a retrospective 
multicenter study from Spain revealed that spontaneous re-
mission occurred in 31.7% of IMN patients with nephrotic 
syndrome (104/328) and in 21.5% among those with pro-
teinuria more than 12 g/day.25 Moreover, time required to 
achieve CR and PR in the Spanish study were 38.5±25.2 
and 14.7±11.4 months, respectively, and the incidence of 
spontaneous remission was substantially increased during the 
follow-up period-up to 20 months.25 Therefore, an apprecia-
ble number of patients in the immunosuppressive treatment 
group of the current study might have a chance to achieve 
spontaneous remission. Despite these limitations, this study 
has a strong point of the inclusion of a large number of pa-
tients and only biopsy-proven IMN patients with nephrotic 
syndrome, who were indeed at a risk of renal progression. 
Furthermore, conservative treatment including RAS block-
ades was universally provided to most patients. Lastly, given 
the lack of data in Asian patients, our findings may provide 
clues for the treatment of IMN in this population.
In conclusion, the present data indicate that corticoste-
roids, either in combination with cyclosporine or alone, may 
induce rapid remission of proteinuria in Korean IMN pa-
tients with nephrotic syndrome. Additionally, renal survival 
in treated patients appears to be improved. Therefore, the 
results warrant a randomized trial of these treatments. The 
stepwise approach presented here may provide a helpful 
guide to physicians in the treatment of IMN.
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